Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Cell therapy
Overview
Autolus Therapeutics
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene Therapy
Overview
Beacon Therapeutics
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Cell therapy companies
Autolus Therapeutics
Achilles Therapeutics
all Gene Therapy companies
Freeline Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
Clear filters
01.12.22
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
Cell therapy
Achilles Therapeutics
15.11.22
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
Operating News
Gene Therapy
Freeline Therapeutics
10.11.22
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
Operating News
Biologics
Anaveon
03.11.22
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
Cell therapy
Autolus Therapeutics
12.09.22
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
Operating News
Biologics
Anaveon
21.07.22
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
Operating News
Gene Therapy
Freeline Therapeutics
Load more
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Cell therapy
Overview
Autolus Therapeutics
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene Therapy
Overview
Beacon Therapeutics
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search